| Catalog Number |
PR301692762 |
| CAS |
301692-76-2 |
| Description |
Polmacoxib has been used in trials studying the treatment of Osteoarthritis, Osteoarthritis, Hip, Osteoarthritis, Knee, Localized Primary Osteoarthritis of Hip, and Localized Primary Osteoarthritis of Knee. |
| IUPAC Name |
4-[3-(3-fluorophenyl)-5,5-dimethyl-4-oxofuran-2-yl]benzenesulfonamide |
| Molecular Weight |
361.4 |
| Molecular Formula |
C18H16FNO4S |
| InChI |
IJWPAFMIFNSIGD-UHFFFAOYSA-N |
| InChI Key |
InChI=1S/C18H16FNO4S/c1-18(2)17(21)15(12-4-3-5-13(19)10-12)16(24-18)11-6-8-14(9-7-11)25(20,22)23/h3-10H,1-2H3,(H2,20,22,23) |
| Documentation/Certification |
Tech Pack |
| Drug Categories |
Amides; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; COX-2 Inhibitors; Cyclooxygenase Inhibitors; Musculo-Skeletal System; Selective Cyclooxygenase 2 Inhibitors (NSAIDs); Sulfones; Sulfur Compounds |
| Drug Interactions |
Abciximab-The risk or severity of bleeding and hemorrhage can be increased when Polmacoxib is combined with Abciximab.
Acebutolol-Polmacoxib may decrease the antihypertensive activities of Acebutolol.
Aceclofenac-The risk or severity of adverse effects can be increased when Aceclofenac is combined with Polmacoxib.
Acemetacin-The risk or severity of adverse effects can be increased when Polmacoxib is combined with Acemetacin.
Acenocoumarol-The risk or severity of bleeding and hemorrhage can be increased when Polmacoxib is combined with Acenocoumarol. |
| Isomeric SMILES |
CC1(C(=O)C(=C(O1)C2=CC=C(C=C2)S(=O)(=O)N)C3=CC(=CC=C3)F)C |
| Standard |
ICH |
| Type |
Small Molecule |
| Therapeutic Category |
Anti-Inflammatory Agents |
It should be noted that our service is only used for research, not for clinical use.
